0000720154FALSE00007201542024-02-072024-02-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 7, 2024
INOTIV, INC.
(Exact name of registrant as specified in its charter)
Indiana 0-23357 35-1345024
(State or other jurisdiction of
 incorporation)		 (Commission File Number) (IRS Employer Identification No.)
2701 KENT AVENUE
WEST LAFAYETTE,INDIANA
 
47906-1382
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (765) 463-4527
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange
 on which registered
Common SharesNOTVThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


The information provided in Item 2.02 and Item 9.01, including Exhibit 99.1, of this Form 8-K is being furnished and shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
Item 2.02.    Results of Operations and Financial Condition.
On February 7, 2024, Inotiv, Inc. issued a press release announcing financial results for the three months ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
Item 9.01.    Financial Statements and Exhibits.
(d)Exhibits
Exhibit
No.		Description
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
INOTIV, INC.
Date:February 7, 2024By:/s/ Beth A. Taylor
Chief Financial Officer,
Senior Vice President—Finance


Exhibit 99.1
Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update

– First quarter fiscal 2024 revenue up 10.3% to $135.5 million
–First quarter fiscal 2024 DSA revenue up 8.8% to $44.7 million and RMS revenue up 11.1% to $90.8 million
–Shift to a renewed focus on sales and marketing as near-term infrastructure projects near completion
–Conference call begins today at 4:30 pm ET
WEST LAFAYETTE, IN, February 7, 2024– Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q1 FY 2024”) ended December 31, 2023.
Revenue by Segment
(in millions of USD)Three months ended
December 31		%
change
20232022
(unaudited)(unaudited)
DSA (Discovery & Safety Assessment)
$44.7$41.18.8%
RMS (Research Models & Services)
$90.8$81.711.1%
Total$135.5$122.810.3%

Management Commentary

Robert Leasure Jr., President and Chief Executive Officer, commented, “Our transformation over the past 18 months has been significant, culminating in the optimization of our operational footprint from 35 to 24 locations, simultaneously expanding three existing facilities and then recently completing the transition of our transportation operations in-house. This will allow us to better service customer demand, add new complementary services and create a platform which will support growth and allow us to leverage our fixed cost structure and enhance margins. As we near the completion of these infrastructure projects, we have shifted to a renewed focus on sales and marketing.

"Our first quarter improvement in the DSA backlog compared to last quarter was a positive. We expect some of this may reflect pent-up demand after a slow summer, but we remain encouraged. The critical groundwork has been completed and we plan to continue building on our strategic initiatives which should improve our efficiencies across our sites and positively impact top and bottom lines,” concluded Mr. Leasure.
Financial Highlights
Q1 FY 2024 Highlights
•Revenue was $135.5 million in Q1 FY 2024 as compared to $122.8 million during the three months ended December 31, 2022 (“Q1 FY 2023”), driven by an increase of $9.1 million, or 11.1%, in Research Models and Services (“RMS”) revenue and an increase of $3.6 million, or 8.8%, in Discovery and Safety Assessment (“DSA”) revenue.
•Consolidated net loss for Q1 FY 2024 was $15.8 million, or 11.7% of total revenue, compared to consolidated net loss of $86.9 million, or 70.8% of total revenue, in Q1 FY 2023.
•Adjusted EBITDA1 in Q1 FY 2024 was $9.6 million, or 7.1% of total revenue, compared to $(5.5) million, or (4.5%) of total revenue, in Q1 FY 2023.
•Net book-to-bill ratio for Q1 FY 2024 was 1.46x for the DSA services business.
•DSA backlog was $152.3 million at December 31, 2023 up from $147.9 million at December 31, 2022, and up from $132.1 million at September 30, 2023.


1 This is a non-GAAP financial measure. Refer to “Non-GAAP to GAAP Reconciliation” in this release for further information.
DSA and RMS Highlights
•In December 2023, the Company announced that it would be partnering with Vanguard Supply Chain Solutions LLC, the Company’s then-current provider of transportation services, to enable the in-house integration of Inotiv’s North American transportation operations. The Company completed this in-house integration in the second quarter of fiscal 2024.
•The expansion activities at Fort Collins, CO, were completed by the end of October 2023 and the expanded site completed the validation of the facility and equipment which became operational in the second quarter of fiscal 2024.
•During the three months ended December 31, 2023, the Company closed the sale of its RMS facilities in Spain and France.
•The Company continues to execute on its site optimization plan for its Blackthorn, UK site. The relocation of operating activities from Blackthorn into its Hillcrest, UK site is expected to be completed by the end of March 2024.
•The Company's facilities in Cumberland and Dublin, Virginia; Haslett, Michigan; and Blackthorn, U.K. are all under contract to be sold and are held for sale as of December 31, 2023.
First Quarter Fiscal 2024 Financial Results (Three Months Ended December 31, 2023)

Revenue increased 10.3% to $135.5 million in Q1 FY 2024 as compared to $122.8 million in Q1 FY 2023. The higher total revenue in the first quarter was driven by a $9.1 million increase in RMS revenue and a $3.6 million increase in DSA revenue.

Operating loss was $9.4 million in Q1 FY 2024 as compared to an operating loss of $90.6 million in Q1 FY 2023. The lower total operating loss in Q1 FY 2024 was primarily the result of an approximately $76.4 million increase in RMS operating income and a decrease in unallocated corporate expenses of approximately $5.7 million, partially offset by an approximately $0.7 million decrease in DSA operating income. The increase in RMS operating income was primarily due to a $66.4 million non-cash goodwill impairment charge in Q1 FY 2023 that did not recur in Q1 FY 2024.

Cash and cash equivalents as of December 31, 2023, was $22.0 million and there were no borrowings on the Company’s $15.0 million revolving credit facility. Cash and cash equivalents of $22.0 million at December 31, 2023 compares to $35.5 million at September 30, 2023, the end of fiscal year 2023. Cash used in operating activities was $6.5 million for Q1 FY 2024, compared to cash used in operating activities of $7.4 million for Q1 FY 2023. For Q1 FY 2024, capital expenditures totaled $5.6 million compared to $8.4 million for Q1 FY 2023. Total debt, net of debt issuance costs, as of December 31, 2023, was $379.3 million. The Company was in compliance with its debt covenants as of December 31, 2023.
Fiscal 2024 Outlook

We reaffirm fiscal 2024 revenues are expected to be in the range of $580 to $590 million and adjusted EBITDA is expected to be in the range of $75 to $80 million.

We expect to continue to remain in compliance with our financial covenants for the next 12 months. We reaffirm that capital expenditures are expected to be approximately 4.5% of revenue in fiscal 2024.
Webcast and Conference Call
Management will host a conference call on Wednesday, February 7, 2024, at 4:30 pm ET to discuss first quarter results for fiscal year 2024.
Interested parties may participate in the call by dialing:
•(877) 704-4453 (Domestic)
•(201) 389-0920 (International)
•13744155 (Conference ID)
The live conference call webcast will be accessible in the Investors section of the Company’s web site and directly via the following link:

https://viavid.webcasts.com/starthere.jsp?ei=1654236&tp_key=c90f5f4d4c

For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Inotiv’s web site at: https://www.inotivco.com/investors/investor-information/.


Non-GAAP to GAAP Reconciliation
This press release contains financial measures that are not calculated in accordance with generally accepted accounting principles in the United States (GAAP), including Adjusted EBITDA and Adjusted EBITDA as a percentage of total revenue for the three months ended December 31, 2023 and 2022 and selected business segment information for those periods. Adjusted EBITDA as reported herein refers to a financial measure that excludes from consolidated net income (loss), statements of operations line items interest expense and income tax (benefit) expense, as well as non-cash charges for depreciation and amortization, stock compensation expense, acquisition and integration costs, startup costs, restructuring costs incurred in connection with the exit of multiple facilities, unrealized foreign exchange gain/loss, amortization of inventory step up, loss/gain on disposition of assets, other unusual third-party costs and goodwill impairment loss. The adjusted business segment information excludes from operating income and unallocated corporate G&A these same expenses.
Adjusted EBITDA guidance for fiscal year 2024 is provided on a non-GAAP basis. The Company cannot reconcile this guidance to expected net income/loss without unreasonable effort because certain items that impact net income/loss and net income/loss margin are out of the Company's control and/or cannot be reasonably predicted at this time, which unavailable information could have a significant impact on the Company’s GAAP financial results.
The Company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the Company’s ongoing operations. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources. Investors should consider these non-GAAP measures as supplemental and in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP.
Management has chosen to provide this supplemental information to investors, analysts, and other interested parties to enable them to perform additional analyses of our results and to illustrate our results giving effect to the non-GAAP adjustments. Management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures.
About the Company
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotivco.com/.
This release contains forward-looking statements that are subject to risks and uncertainties including, but are not limited to, statements regarding our intent, belief or current expectations with respect to (i) our strategic plans; (ii) trends in the demand for our services and products; (iii) trends in the industries that consume our services and products; (iv) our ability to develop new services and products; (v) our ability to source animal research models; (vi) our ability to make capital expenditures, fund our operations and satisfy our obligations; (vii) global economic conditions, especially as they impact our markets; (viii) our cash position; (ix) our ability to successfully integrate the operations and personnel related to acquisitions; (x) our ability to effectively manage current expansion efforts or any future expansion or acquisition initiatives undertaken by us; (xi) our ability to develop and build infrastructure and teams to manage growth and projects; (xii) our ability to continue to retain and hire key talent; (xiii) our ability to market our services and products under our corporate name and relevant brand names; (xiv) our ability to service our outstanding indebtedness and to comply with financial covenants; (xv) our expectations regarding the volume of new bookings, pricing, operating income or losses and liquidity; (xvi) our ability to manage recurring and unusual costs; (xvii) our ability to execute on our restructuring and site optimization plans and to realize the expected benefits related to such actions; and (xviii) the impact of public health emergencies on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address such public health emergencies, which may precipitate or exacerbate other risks and/or uncertainties, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.


Company ContactInvestor Relations
Inotiv, Inc. LifeSci Advisors
Beth A. Taylor, Chief Financial OfficerBob Yedid
(765) 497-8381(516) 428-8577
btaylor@inotivco.combob@lifesciadvisors.com


INOTIV, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended
December 31
20232022
Service revenue$53,863 $50,048 
Product revenue81,638 72,706 
Total revenue135,501 122,754 
Costs and expenses:
Cost of services provided (excluding depreciation and amortization of intangible assets)
39,077 34,001 
Cost of products sold (excluding depreciation and amortization of intangible assets)
62,951 63,263 
Selling5,348 4,501 
General and administrative19,927 28,298 
Depreciation and amortization of intangible assets14,250 13,263 
Other operating expense3,319 3,639 
Goodwill impairment loss— 66,367 
Operating loss
$(9,371)$(90,578)
Other (expense) income:
Interest expense(11,364)(10,450)
Other income (expense)
1,413 (1,878)
Loss before income taxes$(19,322)$(102,906)
Income tax benefit
3,494 15,974 
Consolidated net loss
$(15,828)$(86,932)
Less: Net (loss) income attributable to noncontrolling interests(440)391 
Net loss attributable to common shareholders
$(15,388)$(87,323)
Loss per common share
Net loss attributable to common shareholders:
Basic$(0.60)$(3.41)
Diluted$(0.60)$(3.41)
Weighted-average number of common shares outstanding:
Basic25,76425,603
Diluted25,76425,603


INOTIV, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)
December 31,September 30,
20232023
(Unaudited)
Assets
Current assets:
Cash and cash equivalents$22,001 $35,492 
Trade receivables and contract assets, net of allowances for credit losses of $6,313 and $7,446, respectively89,849 87,383 
Inventories, net50,640 56,102 
Prepaid expenses and other current assets26,264 33,408 
Assets held for sale1,934 1,418 
Total current assets190,688 213,803 
Property and equipment, net191,536 191,068 
Operating lease right-of-use assets, net48,012 38,866 
Goodwill94,286 94,286 
Other intangible assets, net300,350 308,428 
Other assets10,638 10,079 
Total assets$835,510 $856,530 
Liabilities, shareholders' equity and noncontrolling interest
Current liabilities:
Accounts payable$30,716 $32,564 
Accrued expenses and other liabilities23,436 25,776 
Fees invoiced in advance35,821 55,622 
Current portion of long-term operating lease11,105 10,282 
Current portion of long-term debt 8,411 7,950 
Total current liabilities109,489 132,194 
Long-term operating leases, net 38,074 29,614 
Long-term debt, less current portion, net of debt issuance costs370,931 369,795 
Other long-term liabilities17,967 6,373 
Deferred tax liabilities, net44,887 50,064 
Total liabilities581,348 588,040 
Shareholders’ equity and noncontrolling interest:
Common shares, no par value:
Authorized 74,000,000 shares at December 31, 2023 and at September 30, 2023; 25,790,680 issued and outstanding at December 31, 2023 and 25,777,169 at September 30, 2023
6,409 6,406 
Additional paid-in capital715,282 715,696 
Accumulated deficit(469,106)(453,278)
Accumulated other comprehensive income (loss)1,577 330 
Total equity attributable to common shareholders254,162 269,154 
Noncontrolling interest— (664)
Total shareholders’ equity and noncontrolling interest254,162 268,490 
Total liabilities and shareholders’ equity and noncontrolling interest$835,510 $856,530 


INOTIV, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Three Months Ended
December 31,
20232022
Operating activities:
Consolidated net loss$(15,828)$(86,932)
Adjustments to reconcile net loss to net cash used in operating activities, net of acquisitions:
Depreciation and amortization14,250 13,263 
Employee stock compensation expense1,897 2,046 
Changes in deferred taxes(5,318)(20,123)
Provision for expected credit losses(438)1,078 
Amortization of debt issuance costs and original issue discount846 732 
Non-cash interest and accretion expense1,688 1,446 
Other non-cash operating activities(1,249)1,028 
Goodwill impairment loss— 66,367 
Non-cash amortization of inventory fair value step-up102 244 
Changes in operating assets and liabilities:
Trade receivables and contract assets(1,497)21,999 
Inventories6,058 (4,204)
Prepaid expenses and other current assets7,096 7,810 
Operating lease right-of-use assets and liabilities, net138 266 
Accounts payable(2,845)1,169 
Accrued expenses and other liabilities(2,497)(5,548)
Fees invoiced in advance(20,012)(7,796)
Other asset and liabilities, net11,064 (255)
Net cash used in operating activities(6,545)(7,410)
Investing activities:
Capital expenditures(5,572)(8,369)
Proceeds from sale of equipment1,529 211 
Net cash used in investing activities(4,043)(8,158)
Financing activities:
Payments on revolving credit facility— (15,000)
Payments on senior term notes and delayed draw term loans(691)(688)
Borrowings on senior term notes and delayed draw term loans— 35,000 
Other financing activities, net(2,230)(928)
Net cash (used in) provided by financing activities(2,921)18,384 
Effect of exchange rate changes on cash and cash equivalents18 593 
Net increase (decrease) in cash and cash equivalents(13,491)3,409 
Less: cash, cash equivalents, and restricted cash held for sale— (1,569)
Cash, cash equivalents, and restricted cash at beginning of period35,492 18,980 
Cash, cash equivalents, and restricted cash at end of period$22,001 $20,820 
Supplemental disclosure of cash flow information:
Cash paid for interest$11,068 $8,491 
Income taxes paid, net$298 $2,268 


INOTIV, INC.
RECONCILIATION OF GAAP TO NON-GAAP
SELECT BUSINESS SEGMENT INFORMATION
(In thousands)
(Unaudited)
 Three Months Ended December 31,
 20232022
DSA
Revenue44,698 41,093 
Operating income
1,593 2,372 
Operating income as a % of total revenue
1.2 %1.9 %
Add back:  
Depreciation and amortization4,409 3,980 
Restructuring costs113 — 
Startup costs830 1,505 
Total non-GAAP adjustments to operating income5,352 5,485 
Non-GAAP operating income6,945 7,857 
Non-GAAP operating income as a % of DSA revenue15.5 %19.1 %
Non-GAAP operating income as a % of total revenue5.1 %6.4 %
 
RMS  
Revenue90,803 81,661 
Operating income (loss)
5,078 (71,272)
Operating income (loss) as a % of total revenue
3.7 %(58.1 %)
Add back:  
Depreciation and amortization9,737 9,283 
Restructuring costs921 266 
Amortization of inventory step up102 244 
 Other unusual, third party costs
1,086 671 
 Goodwill impairment loss— 66,367 
Total non-GAAP adjustments to operating income (loss)
11,846 76,831 
Non-GAAP operating income16,924 5,559 
Non-GAAP operating income as a % of RMS revenue18.6 %6.8 %
Non-GAAP operating income as a % of total revenue12.5 %4.5 %


 Three Months Ended December 31,
 20232022
Unallocated Corporate Operating Expenses(16,042)(21,678)
Unallocated corporate operating expenses as a % of total revenue(11.8)%(17.7)%
Add back:
Depreciation and amortization104 — 
Stock option expense1,897 2,046 
Acquisition and integration costs70 983 
Total non-GAAP adjustments to operating loss
2,071 3,029 
Non-GAAP operating loss(13,971)(18,649)
Non-GAAP operating loss as a % of total revenue(10.3)%(15.2)%
Total
Revenue135,501 122,754 
Operating loss
(9,371)(90,578)
Operating loss as a % of total revenue
(6.9)%(73.8 %)
Add back:
Depreciation and amortization14,250 13,263 
Stock compensation expense1,897 2,046 
Restructuring costs1,034 266 
Acquisition and integration costs70 983 
Amortization of inventory step up102 244 
Startup costs830 1,505 
 Other unusual, third party costs
1,086 671 
 Goodwill impairment loss- 66,367 
Total non-GAAP adjustments to operating loss
19,269 85,345 
Non-GAAP operating income (loss)
9,898 (5,233)
Non-GAAP operating income (loss) as a % of total revenue
7.3 %(4.3 %)


INOTIV, INC.
RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA
(In thousands)
(Unaudited)
 Three Months Ended
December 31
 20232022
GAAP Consolidated Net Loss
$(15,828)$(86,932)
Adjustments (a):  
Interest expense11,364 10,450 
Income tax benefit
(3,494)(15,974)
Depreciation and amortization14,250 13,263 
Stock compensation expense1,897 2,046 
Acquisition and integration costs (1)70 983 
Startup costs830 1,505 
Restructuring costs (2)1,034 266 
Unrealized foreign exchange (gain) loss
(1,029)1,250 
Amortization of inventory step up102 244 
(Gain) loss on disposition of assets
(666)380 
Other unusual, third party costs
1,086 671 
Goodwill impairment loss (3)
- 66,367 
Adjusted EBITDA (b)$9,616 $(5,481)
GAAP consolidated net loss as a percent of total revenue
(11.7)%(70.8)%
Adjustments as a percent of total revenue18.8 %66.4 %
Adjusted EBITDA as a percent of total revenue7.1 %(4.5 %)
(a)Adjustments to certain GAAP reported measures for the three months ended December 31, 2023 and 2022 include, but are not limited to, the following:
(1)For the three months ended December 31, 2023 and 2022, represents charges for legal services, accounting services, travel and other related activities in connection with various acquisitions and the related integration of those acquisitions.
(2)For the three months ended December 31, 2023, represents costs incurred in connection with the exit of multiple sites and the enablement of the in-house integration of Inotiv’s North American transportation operations as previously disclosed. For the three months ended December 31, 2022, represents costs incurred in connection with the exit of multiple sites as previously disclosed.
(3)For the three months ended December 31, 2022, represents a non-cash goodwill impairment charge of $66.4 million related to the RMS segment.
(b)Adjusted EBITDA - Consolidated net income (loss) before interest expense, income tax expense (benefit), depreciation and amortization, stock compensation expense, acquisition and integration costs, startup costs, restructuring costs, unrealized foreign exchange gain/loss, amortization of inventory step up, gain/loss on disposition of assets, other unusual third party costs and goodwill impairment loss.

v3.24.0.1
Cover
Feb. 07, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 07, 2024
Entity Registrant Name INOTIV, INC.
Entity Incorporation, State or Country Code IN
Entity File Number 0-23357
Entity Tax Identification Number 35-1345024
Entity Address, Address Line One 2701 KENT AVENUE
Entity Address, City or Town WEST LAFAYETTE
Entity Address, State or Province IN
Entity Address, Postal Zip Code 47906
City Area Code 765
Local Phone Number 463-4527
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares
Trading Symbol NOTV
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0000720154
Amendment Flag false
Inotiv (NASDAQ:NOTV)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Inotiv Charts.
Inotiv (NASDAQ:NOTV)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Inotiv Charts.